- IBDoc® Patient Support
Switching to the new fPELA turbo assay for improved workflow and efficiency Kaleem Fayyaz, Blood Sciences Team Leader, Spire Manchester Hospital Spire Healthcare is a leading UK independent hospital group.
An interview with Yvonne Schallberger, Bioanalytica, Lucerne, Switzerland Mrs. Schallberger decided to introduce the BÜHLMANN fPELA® turbo Test, that measures in random access as well as in batch mode the
Testimonial from Angela Suter and Dr. Cyril Fuhrer, Synlab Suisse SA, Lucerne, Switzerland You are successfully performing routine faecal calprotectin measurements with the BÜHLMANN fCAL® turbo Assay on the Beckman
A report from Dr. Marc-Antoine Bagnoud*, Dianalabs in Geneva, Switzerland Dianalabs is a mid-sized private lab founded in 1988 in Geneva, Switzerland, and part of the large swiss lab network
Launched in summer 2020, the new BÜHLMANN fPELA turbidimetric immunoassay for faecal pancreatic elastase, complements the popular calprotectin fCAL turbo assay, that is widely used across the UK. Using the
Dr. Jörg Oliver Thumfart, Labormedizinisches Zentrum Dr. Risch The Medical Laboratory Center Dr. Risch is a privately owned group of routine medical laboratories with 14 competence centres across Switzerland and
A report from Dr. Jörg Oliver Thumfart*, Labormedizinisches Zentrum Dr. Risch “We successfully introduced the automated, turbidimetric assay for fecal calprotectin, the BÜHLMANN fCAL® turbo, on our Roche cobas® c501